ALK and non-small cell lung carcinoma: In addition, a subset of ALK-positive NSCLC patients may undergo SCLC-like transformation during therapy, exhibiting neuroendocrine differentiation and loss of ALK dependency, which leads to a precipitous decline in therapeutic efficacy [75].